BAT, through one of its wholly-owned subsidiaries, has acquired a non-controlling minority stake in Sanity Group, one of Germany's leading cannabis companies.
I'm sorry, but "Greenserenityca" does not make sense as a sentence or phrase in English, and therefore cannot be translated into standard journalistic English. Please provide a valid sentence or phrase to be translated.
This investment is a supplement to other recent investments made by BAT, the most notable being the strategic research and development partnership announced with Canada's Organigram Holdings in March of last year.
The Sanity Group, headquartered in Berlin, produces both consumer-focused CBD brands and medical cannabis brands, with a strong record of research, development, and marketing in the cannabis industry.
Kingsley Wheaton, the Chief Growth Officer of BAT, stated in a press release that the investment in Sanity Group is another example of BAT's exploration beyond nicotine and lays the foundation for BAT's future growth in various categories and regions.
We will continue to transform our business by better understanding our current and future consumers, which is part of our 'Better Tomorrow' objective.
Sanity, according to its founder and CEO Finn Age Hansel, has secured $37.6 million in funding during the second round of financing led by BAT. Approximately half of the funds will be allocated to strengthening Sanity's medical businesses while the remaining funds will be directed towards preparing for possible legalization of recreational marijuana in Germany.
Germany has not yet legalized recreational marijuana, but it is expected to do so sooner or later. Hansel stated that the German coalition government is "actively working" and "really hopes to develop a good draft law by the end of this year." "This is indeed a government priority.
This funding is an important milestone for us and a strong signal for the future of cannabis in Germany and Europe," said Max Narr, Chief Investment Officer of Sanity Group. "In the midst of a challenging global economy, we are proud to have secured such a significant amount of financing.
Statement:
This article is compiled from third-party information and is intended for industry-related communications and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the truthfulness and accuracy of the article's content. The compilation of this article is only intended for industry exchange and research.
Due to limitations in our translation abilities, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government concerning any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
